Michael McHale
University of California, San Diego
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Michael McHale as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:27 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT03287271 · ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAKMichael McHale · terminated · Ovarian Cancer · principal investigator
- Ph1NCT02589366 · Lymphoseek as Lymphoid Tissue Targeting Agent in Patients With Cancer of the EndometriumUniversity of California, San Diego · terminated · Endometrial Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:27 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:27 UTC. The ranking covers the 200 most relevant of 15 PubMed records, and a shared surname and initials can bring in a namesake. All 15 on PubMed
- Maraviroc for previously treated patients with R5 HIV-1 infection.N Engl J Med · 2008619 citationsRCR 14.6
- Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.Lancet Oncol · 2020202 citationsRCR 7.7
- Bone Marrow-sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin For Stage IB-IVA Cervical Cancer: An International Multicenter Phase II Clinical Trial (INTERTECC-2).Int J Radiat Oncol Biol Phys · 2017126 citationsRCR 5.3
- Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study.Gynecol Oncol · 202060 citationsRCR 2.6
- Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer.J Immunother Cancer · 202257 citationsRCR 3.4
- A randomized, double blind, Phase III trial using oral beta-carotene supplementation for women with high-grade cervical intraepithelial neoplasia.Cancer Epidemiol Biomarkers Prev · 200140 citationsRCR 1.1
- Positron Emission Tomography-Guided Bone Marrow-Sparing Radiation Therapy for Locoregionally Advanced Cervix Cancer: Final Results From the INTERTECC Phase II/III Trial.Int J Radiat Oncol Biol Phys · 202236 citationsRCR 3.0
- A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers.Invest New Drugs · 201823 citationsRCR 0.7
- 22 citationsRCR 1.7
- First-in-Human Study With the Inhaled TLR9 Oligonucleotide Agonist AZD1419 Results in Interferon Responses in the Lung, and Is Safe and Well-Tolerated.Clin Pharmacol Ther · 201821 citationsRCR 0.8